For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() The Cigna GroupCI US · Health Care · USD Current price$273.04as of Nov 19, 2026 Summary
Analyst consensusStrong Buy 6Buy 12Hold 625 analysts 3-year price (USD)Factor profileMulti-factor score 92 / 100 Market data
Business descriptionThe Cigna Group is one of the largest U.S. employee benefits organizations, operating through two primary segments: Evernorth Health Services (79% of 2025 adjusted revenues), which provides pharmacy benefit management, specialty pharmacy, and behavioral health services; and Cigna Healthcare (21%), which offers commercial medical insurance domestically and internationally. Following the divestiture of its Medicare businesses, CI is now a focused commercial health + PBM operator with reduced federal government exposure. Competitive moat
Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Nov 13, 2026
Current price: $273.04 · Nov 19, 2026· USD
CFRA Ratingbuy
TBI Multi Score92
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart (TradingView)
Symbol: CIBusiness description
The Cigna Group is one of the largest U.S. employee benefits organizations, operating through two primary segments: Evernorth Health Services (79% of 2025 adjusted revenues), which provides pharmacy benefit management, specialty pharmacy, and behavioral health services; and Cigna Healthcare (21%), which offers commercial medical insurance domestically and internationally. Following the divestiture of its Medicare businesses, CI is now a focused commercial health + PBM operator with reduced federal government exposure.
Competitive moat
- Second-largest U.S. employee benefits organization by revenue, with significant scale in both commercial health insurance and PBM operations.
- Evernorth franchise benefits from a sticky pharmacy benefit platform processing 2.22B claims in 2025, with long-duration client relationships.
- Centene PBM services agreement (estimated 20M members won from CVS) demonstrates competitive win capability in PBM market share battles.
- Streamlined portfolio post-Medicare divestiture allows sharper focus on commercial health and pharmacy, improving margin profile.
- Low valuation (9.3x forward P/E) with strong buyback potential provides downside protection.
Recent developments
- Medicare divestiture closed (March 2025): Sold Medicare Advantage, Part D, and CareAllies to HCSC for $4.9B; CI now focused on Commercial + PBM with less federal exposure.
- FTC/Express Scripts settlement (February 2026): Resolved antitrust lawsuit over insulin pricing; agreed to concessions including moving Ascent GPO to U.S. and joining TrumpRx, reducing regulatory overhang.
- Q1 2026 beat: Adjusted EPS of $7.79 (+16% Y/Y) exceeded consensus by $0.18; full-year guidance raised $0.10. Evernorth revenues up 9% Y/Y.
- Planned ACA exit: CI will exit Individual ACA Exchange market by year-end 2026, citing limited scale relative to portfolio.
Investment risks / red flags
- Membership declines: Total medical customers fell ~5% in 2025 following divestitures; medical customer growth expected flat in 2026.
- Medical utilization pressure: Industrywide cost pressures from stop-loss plans and deferred care; MCR maintained at 83.7%-84.7% guidance reflects ongoing uncertainty.
- PBM regulatory risk: Intense political scrutiny on PBM rebate models; FTC action and Trump administration policies could pressure Evernorth economics.
- Leverage: Total debt/capital of ~39% following Express Scripts acquisition; though steadily deleveraging.
Market Data
Source: mkts.io · Nov 19, 2026, 22:01 UTC
Key Metrics
P/E (TTM)12.04
P/E (Fwd)8.20
Dividend2.19%
Beta0.25
52W High$318.05
52W Low$257.85
Analyst Consensus
6
12
6
Strong Buy6Buy12Hold625 analysts
Consensus Target$344.40
+26.1% upside
Calendar Events
Next EarningsFeb 4, 2027
Ex-DividendDec 3, 2026
Dividend DateDec 17, 2026
Financials
Revenue$286.32B
Rev Growth5.60%
Earnings Growth-21.60%
Gross Margin9.09%
Op Margin3.79%
Profit Margin2.09%
EBITDA$12.74B
ROA4.29%
ROE15.65%
Rev/Share$1.09K
Total Cash$7.30B
Total Debt$31.14B
D/E Ratio71.23
Free Cash Flow$8.19B
Op Cash Flow$9.43B
Current Ratio0.84
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 7.14 | $75.05B |
| +1q | 8.39 | $71.67B |
| 0y | 30.66 | $288.62B |
| +1y | 33.28 | $299.63B |
Earnings
Quarterly EPS
4Q2025
Est: 7.888.08Beat
1Q2026
Est: 7.617.79Beat
2Q2026
Est: 7.607.78Beat
3Q2026
Est: 7.517.98Beat
Annual
2022
Rev $180.64BEarn $6.67B
2023
Rev $195.32BEarn $5.16B
2024
Rev $247.10BEarn $3.43B
2025
Rev $274.90BEarn $5.96B
Rating Changes
| Date | Firm | Action | To |
|---|---|---|---|
| Nov 12, 2026 | Jefferies | main | Hold |
| Nov 12, 2026 | Piper Sandler | main | Overweight |
| Nov 11, 2026 | Bernstein | main | Outperform |
| Nov 9, 2026 | Barclays | main | Equal-Weight |
| Nov 6, 2026 | Evercore ISI Group | main | In-Line |
| Nov 6, 2026 | Guggenheim | main | Buy |
